Press Releases

 
Press Releases
  Date Title View
Apr 14, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Christine van Heek has been appointed to its Board of Directors and will serve as a member of its audit committee effective April 8, 2016. Ms. van Heek has more than 30 years of experience in the healthc...
Mar 23, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Meghan FitzGerald has been appointed to its Board of Directors and will serve as a member of its compensation committee effective March 22, 2016. "We are delighted to welcome Meg to our B...
Mar 1, 2016
- Focus on Clinical Program Advancement in 2016 - - CTP-656 Solid Dose Phase 1 Results Confirmed Superior Pharmacokinetic Profile to Kalydeco® - - Conference Call Scheduled Today at 8:30 a.m. ET - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert ...
Feb 29, 2016
Conference Call Scheduled Tomorrow at 8:30 a.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced new results from Part 1 of its multiple ascending dose Phase 1 clinical trial in which a single-dose tablet formulation of CTP-656 was ...
Feb 29, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The 36th Annual Cowen and Company Healthcare Conference on March 7, 2016 at 2:0...
Feb 23, 2016
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2015, on Tuesday, March 1, 2016, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a...
Nov 16, 2015
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the progression of the clinical development of AVP-786. The milestone is a result of Avanir ...
Nov 12, 2015
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 multiple ascending dose clinical trial with CTP-656. CTP-656 (deuterium-modified ivacaftor) is a novel, potentially disease-modifying treatment for cystic fibrosis for use as m...
Nov 9, 2015
LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2...
Nov 5, 2015
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2015. "We have made progress with multiple drug candidates across our diverse ...
FirstPrevious
3
...
NextLast
= add release to Briefcase